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Alopecia areata (AA) is a common autoimmune disease of
the hair follicles that causes nonscarring hair loss.1,2 It most
frequently affects the scalp; however, it may involve any
hair-bearing site on the body. The pivotal role of hair in a
person’s appearance and expressing one’s identity is well
known. Patients with AA face the psychological impact of
losing their hair, which may lead to lower self-esteem,
higher level of anxiety and depression and poorer health-
related quality of life (HRQoL).3–5 Physicians and patients
often have different perceptions about the disease, expecta-
tions about treatments and preferences for outcomes. In
recent years, understanding the subjectivity of patients’ per-
ceptions, emotions and needs, has led to the development of
a growing number of AA-specific patient-reported outcome
measures (PROMs). Some of these measures, such as the
Alopecia Areata Symptom Impact Scale6 and the Alopecia
Areata Quality of Life Index (AA-QLI)7 ask patients both
about their objective symptoms and HRQoL, whereas other
instruments, such as the Alopecia Areata Quality of Life,8
specifically address various domains of disease-specific
HRQoL, for example, restriction of activities, concealment
and adaptation. These AA-specific PROMs are typically longer,
consisting of seven to 21 questionnaire items.
In this issue of BJD, Wyrwich et al. reported on the develop-
ment a new, AA-specific PROM to assess disease severity of
scalp hair loss.9 The Scalp Hair Assessment PROTM has been
developed and refined using cognitive interviewing with 45
patients with AA in the USA. Concept elicitation revealed that
among the several characteristics describing the hair loss or
regrowth (e.g. location, quantity and thickness), quantity was
the most important factor for patients with AA. Building on
this, the authors developed an easy-to-use single-item instru-
ment that allows patients to rate their hair loss in terms of
quantity. The percentage of scalp surface with missing hair is
measured on a five-point scale (0%, no missing hair; 1–20%,
limited; 21–49%, moderate; 50–94%, large; 95–100%, nearly
all or all). Patients with AA participating in the cognitive inter-
views agreed that having ≤ 20% missing hair indicated a treat-
ment success on this scale. Advantages of the new PROM
include simplicity, low patient burden and comparability with
the Alopecia Areata Investigator Global Assessment (AA-IGA)
measure.10 On the other hand, its brevity may also be viewed
as a weakness because other symptoms possibly relevant for
patients with AA, such as itch, irritation and pain of the scalp,
body hair loss or nail involvement, are not covered by the sin-
gle-item instrument.
The Scalp Hair Assessment PROTM seems to be a content-
valid and practical PROM for patients with AA that can be
used for monitoring treatment effects and hair loss or
regrowth in various clinical and research settings, such as
patient diaries and clinical trials. Nevertheless, in spite of the
positive evidence of content validity, its psychometric perfor-
mance in various patient populations, including construct
validity, test–retest reliability, responsiveness and agreement
with AA-IGA, requires further evaluation.
F. Rencz iD 1,2
1Department of Health Economics, Corvinus University of Budapest, 8 F}ovam ter,
H-1093, Budapest, Hungary and 2Premium Postdoctoral Research Programme,
Hungarian Academy of Sciences, 7 Nador u., H-1051, Budapest, Hungary
Email: fanni.rencz@uni-corvinus.hu
Conflicts of interest: none to declare.
References
1 Pratt CH, King LE Jr, Messenger AG et al. Alopecia areata. Nat Rev
Dis Primers 2017; 3:17011.
2 Strazzulla LC, Wang EHC, Avila L et al. Alopecia areata: disease
characteristics, clinical evaluation, and new perspectives on patho-
genesis. J Am Acad Dermatol 2018; 78:1–12.
3 Rencz F, Gulacsi L, Pentek M et al. Alopecia areata and health-
related quality of life: a systematic review and meta-analysis. Br J
Dermatol 2016; 175:561–71.
4 Russo PM, Fino E, Mancini C et al. HrQoL in hair loss-affected
patients with alopecia areata, androgenetic alopecia and telogen
effluvium: the role of personality traits and psychosocial anxiety. J
Eur Acad Dermatol Venereol 2019; 33:608–11.
5 Titeca G, Goudetsidis L, Francq B et al. ‘The psychosocial burden
of alopecia areata and androgenetica’: a cross-sectional multicentre
study among dermatological out-patients in 13 European coun-
tries. J Eur Acad Dermatol Venereol 2020; 34:406–11.
6 Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the Alope-
cia Areata Symptom Impact Scale. J Investig Dermatol Symp Proc 2013;
16:S51–2.
7 Fabbrocini G, Panariello L, De Vita V et al. Quality of life in alope-
cia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol
2013; 27:e276–81.
8 Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific
instrument to measure quality of life in patients with alopecia
areata. Eur J Dermatol 2012; 22:531–6.
9 Wyrwich KW, Kitchen H, Knight S et al. Development of the Scalp
Hair Assessment PROTM measure for alopecia areata. Br J Dermatol
2020; https://doi.org/10.1111/bjd.19024. [Epub ahead of print].
10 Wyrwich KW, Kitchen H, Knight S et al. The Alopecia Areata
Investigator Global Assessment scale: a measure for evaluating clin-
ically meaningful success in clinical trials. Br J Dermatol 2020;
https://doi.org/10.1111/bjd.18883.
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2020) 1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
